Literature DB >> 26317459

PD-1 Blockers.

Jedd D Wolchok1.   

Abstract

Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26317459     DOI： 10.1016/j.cell.2015.07.045

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  64 in total

Review 1.  Immunotherapy meets targeted therapy: will this team end the war against cancer?

Authors:  Daniela Morales-Espinosa; Silvia García-Román; Cristina Teixidó; Niki Karachaliou; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2015-12

Review 2.  Cardiovascular Risk in Cancer Survivors.

Authors:  Inbar Agmon Nardi; Zaza Iakobishvili
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-28

3.  Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma.

Authors:  Bangrong Cao; Qifeng Wang; Huan Zhang; Guiquan Zhu; Jinyi Lang
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

Review 4.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

5.  Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications.

Authors:  Jinru Shia; Nikolaus Schultz; Deborah Kuk; Efsevia Vakiani; Sumit Middha; Neil H Segal; Jaclyn F Hechtman; Michael F Berger; Zsofia K Stadler; Martin R Weiser; Jedd D Wolchok; C Richard Boland; Mithat Gönen; David S Klimstra
Journal:  Mod Pathol       Date:  2016-12-16       Impact factor: 7.842

6.  Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients.

Authors:  Douglas B Johnson; Kevin B Taylor; Justine V Cohen; Noura Ayoubi; Alexandra M Haugh; Daniel Y Wang; Brian D Schlick; Amber L Voorhees; Kenneth L Gage; Florian J Fintelmann; Ryan J Sullivan; Zeynep Eroglu; Richard G Abramson
Journal:  Cancer Immunol Res       Date:  2019-08-28       Impact factor: 11.151

7.  Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.

Authors:  Peter J Siska; Romany A N Johnpulle; Alice Zhou; Jennifer Bordeaux; Ju Young Kim; Bashar Dabbas; Naveen Dakappagari; Jeffrey C Rathmell; W Kimryn Rathmell; Alicia K Morgans; Justin M Balko; Douglas B Johnson
Journal:  Oncoimmunology       Date:  2017-03-20       Impact factor: 8.110

Review 8.  Toxicities Associated With PD-1/PD-L1 Blockade.

Authors:  Daniel Y Wang; Douglas B Johnson; Elizabeth J Davis
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

Review 9.  Strategies to Prevent Cardiotoxicity.

Authors:  Jason Graffagnino; Lavanya Kondapalli; Garima Arora; Riem Hawi; Carrie G Lenneman
Journal:  Curr Treat Options Oncol       Date:  2020-04-08

10.  Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing.

Authors:  Elizabeth J Davis; Douglas B Johnson
Journal:  Per Med       Date:  2017-05-05       Impact factor: 2.512
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.